Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 9/20 | 0.71 |
| ▸ | LMNA | P02545 | 7/20 | 0.71 |
| ▸ | HTT | P42858 | 7/20 | 0.71 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.64 |
| ▸ | RAB9A | P51151 | 4/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.62 |
| ▸ | NPC1 | O15118 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.60 |
| ▸ | NAMPT | P43490 | 2/20 | 0.59 |
| ▸ | GALR3 | O60755 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27083360 | 0.85 | SMN1; SMN2 (0.73) | SMN1; SMN2LMNAHTTRAB9AALDH1A1 | |
| SCHEMBL7956461 | 0.84 | ALDH1A1 (0.54) | SMN1; SMN2LMNAHTTCYP19A1RAB9A | |
| SCHEMBL29258245 | 0.83 | NAMPT (0.86) | NAMPT | |
| SCHEMBL4895465 | 0.83 | SMN1; SMN2 (0.71) | SMN1; SMN2LMNAHTTRAB9AALDH1A1 | |
| SCHEMBL7663045 | 0.83 | SMN1; SMN2 (0.71) | SMN1; SMN2LMNAHTTRAB9AALDH1A1 | |
| SCHEMBL4662893 | 0.83 | SMN1; SMN2 (1.00) | SMN1; SMN2LMNAHTTRAB9AALDH1A1 | |
| SCHEMBL2831966 | 0.83 | CYP19A1 (0.78) | SMN1; SMN2LMNACYP19A1ALDH1A1CYP1A2 | |
| SCHEMBL29258266 | 0.83 | NAMPT (0.65) | SMN1; SMN2ALDH1A1NAMPT | |
| SCHEMBL12078116 | 0.82 | NAMPT (0.60) | SMN1; SMN2LMNAALDH1A1NAMPT | |
| SCHEMBL1581598 | 0.81 | CYP2C19 (0.67) | SMN1; SMN2LMNAHTTCYP19A1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240043384-A1 | INHIBITORS OF PU.1 FOR THE TREATMENT OF DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2024-02-08 | — | — | US | disclosed |
| WO-2022217239-A1 | INHIBITORS OF PU.1 FOR THE TREATMENT OF DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-10-13 | — | — | WO | disclosed |
| US-9550783-B2 | Biaryl heterocyclic compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-9550783-B2 | Biaryl heterocyclic compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-20150072970-A1 | BIARYL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | MELINTA THERAPEUTICS, INC. (US) | 2015-03-12 | — | — | US | disclosed |
| US-20150072970-A1 | BIARYL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | MELINTA THERAPEUTICS, INC. (US) | 2015-03-12 | — | — | US | disclosed |
| US-8895741-B2 | Process for the synthesis of biaryl oxazolidinones | MELINTA THERAPEUTICS, INC. (US) | 2014-11-25 | — | — | US | disclosed |
| US-8895741-B2 | Process for the synthesis of biaryl oxazolidinones | MELINTA THERAPEUTICS, INC. (US) | 2014-11-25 | — | — | US | disclosed |
| US-20140073624-A1 | Biaryl Heterocyclic Compounds and Methods of Making and Using the Same | RIB-X PHARMACEUTICALS, INC. (US) | 2014-03-13 | — | — | US | disclosed |
| US-20140073624-A1 | Biaryl Heterocyclic Compounds and Methods of Making and Using the Same | RIB-X PHARMACEUTICALS, INC. (US) | 2014-03-13 | — | — | US | disclosed |
| US-20100234591-A1 | BIARYL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | RIB-X PHARMACEUTICALS, INC. (US) | 2010-09-16 | — | — | US | disclosed |
| US-20100234591-A1 | BIARYL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | RIB-X PHARMACEUTICALS, INC. (US) | 2010-09-16 | — | — | US | disclosed |
| US-7705026-B2 | Biaryl heterocyclic compounds and methods of making and using the same | RIB-X PHARMACEUTICALS, INC. (US) | 2010-04-27 | — | — | US | disclosed |
| US-7705026-B2 | Biaryl heterocyclic compounds and methods of making and using the same | RIB-X PHARMACEUTICALS, INC. (US) | 2010-04-27 | — | — | US | disclosed |
| US-20100022772-A1 | PROCESS FOR THE SYNTHESIS OF BIARYL OXAZOLIDNONES | RIB-X PHARMACEUTICALS, INC. (US) | 2010-01-28 | — | — | US | disclosed |
| US-20100022772-A1 | PROCESS FOR THE SYNTHESIS OF BIARYL OXAZOLIDNONES | RIB-X PHARMACEUTICALS, INC. (US) | 2010-01-28 | — | — | US | disclosed |
| EP-2035372-A1 | MODULATORS OF THE HISTAMINE H3-RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2009-03-18 | — | — | EP | disclosed |
| US-7456206-B2 | Biaryl heterocyclic compounds and methods of making and using the same | RIB-X PHARMACEUTICALS, INC. (US) | 2008-11-25 | — | — | US | disclosed |
| US-7456206-B2 | Biaryl heterocyclic compounds and methods of making and using the same | RIB-X PHARMACEUTICALS, INC. (US) | 2008-11-25 | — | — | US | disclosed |
| WO-2008005338-A1 | MODULATORS OF THE HISTAMINE H3-RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234591-A1 | BIARYL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | PCNA, AADAC, MIF | SMN1; SMN2 4396/4885LMNA 910/4885HTT 506/4885 |
| US-20240043384-A1 | INHIBITORS OF PU.1 FOR THE TREATMENT OF DISEASE | CREBBP, JUN, SP1 | SMN1; SMN2 763/4885LMNA 2795/4885HTT 645/4885 |
| US-20150072970-A1 | BIARYL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | PCNA, AADAC, MIF | SMN1; SMN2 4396/4885LMNA 910/4885HTT 506/4885 |
| US-20100022772-A1 | PROCESS FOR THE SYNTHESIS OF BIARYL OXAZOLIDNONES | PCNA, PGC, MKI67 | SMN1; SMN2 3267/4885LMNA 1264/4885HTT 2244/4885 |
| US-20140073624-A1 | Biaryl Heterocyclic Compounds and Methods of Making and Using the Same | PCNA, AADAC, MIF | SMN1; SMN2 4396/4885LMNA 910/4885HTT 506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.